Trial Search Results
TAXUS Libertē Post Approval Study
The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen.
This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Study).
Stanford is currently not accepting patients for this trial.
Boston Scientific Corporation
Collaborator: Daiichi Sankyo, Inc.
- Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent
- Drug: prasugrel
- Drug: placebo
- Drug: aspirin
Enrollment Inclusion Criteria
- Patient is > 18 years of age.
- Consecutive patients who have signed an Informed Consent Form, who do not otherwise
meet applicable exclusion criteria, and who are eligible to receive a TAXUS Liberté
Stent and the study required DAPT will be evaluated for enrollment in this study.
Enrollment Exclusion Criteria
- Patient with known hypersensitivity to paclitaxel or structurally related compounds.
- Patient with known hypersensitivity to the polymer or any of its individual
- Patient judged to have a lesion that prevents complete inflation of an angioplasty
balloon or proper placement of the stent or delivery device.
- Patient who cannot receive the protocol required dual antiplatelet therapy.
- Patient on warfarin or similar anticoagulant therapy.
- Patient with known pregnancy.
- Planned surgery necessitating discontinuation of antiplatelet therapy(> 14 days)within
the 30-months following enrollment.
- Current medical condition with a life expectancy of less than 3 years.
- Patient currently enrolled in another device or drug study whose protocol specifically
excludes concurrent enrollment or that involves blinded placement of a drug-eluting
stent other than the TAXUS Liberté Stent.
- Patient judged unable to cooperate with prolonged DAPT.
- Patient unable to give informed consent.
- Patient judged inappropriate for randomization due to other condition requiring
chronic thienopyridine use.
- Patient treated with both a drug-eluting stent and a bare-metal stent during the index
- Patient who experienced a prior transient ischemic attack (TIA) or a prior stroke.
- Patient requiring chronic daily use (greater than 2 consecutive weeks) of
non-steroidal anti-inflammatory drugs (NSAIDs) with the exception of aspirin.
Occasional use of NSAIDs on an as needed or "prn" schedule is not exclusionary.
- Patient with active pathological bleeding (such as peptic ulcer or intracranial
Additional Exclusion Criteria (applicable only after patient enrollment has reached
- Patient who experienced a myocardial infarction (MI) within 72 hours prior to the
- Patient with a history of (includes current) left main coronary artery disease.
- Patient who requires stenting of > 1 vessel with a TAXUS Liberté stent during the
- Patient who requires stenting of > 2 vessels during the index procedure.
- Patient who requires a staged procedure within 6-weeks following the index procedure,
in whom > 1 vessel was stented during the index procedure.
- Patient with cardiogenic shock.
- Patient with acute or chronic renal dysfunction (serum creatinine >3.0 mg/dl or
patient receiving dialysis).
- Target Lesion that meets any of the following criteria:
- Located within a saphenous vein graft or an arterial graft
- Chronic total occlusion
- Restenosis from a previously implanted drug-eluting or bare-metal stent
- Previous use of intravascular brachytherapy in target vessel
- Lesion involves a bifurcation
- Lesion is ostial in location
- Severe tortuosity in the target lesion or target vessel proximal to the target
- Moderate or severe calcification by visual estimate in the target lesion or
target vessel proximal to the target lesion
- RVD < 2.5 mm or RVD > 3.75 mm
- Lesion length > 28 mm
Randomization Inclusion Criteria (12-months):
- Patient is "12-Month Clear," which is defined as patients enrolled in the study who
are free from all death, MI, stroke, repeat coronary revascularization, stent
thrombosis and major bleeding (severe or moderate by GUSTO classification) 12 months
after stent implantation and who are compliant with 12 months of DAPT following stent
implantation. Exceptions to this rule are: Patients who experience repeat PCI, stent
thrombosis and/or myocardial infarction occurring within 6 weeks after the index
procedure will not be excluded from the definition of 12-Month Clear.
- Patient was compliant with DAPT during the first 12 months of the study. Compliance is
defined as the patient taking between 80% and 120% of prasugrel in the 0-6 month and
6-12 month periods without an interruption of therapy longer than 14 days. Compliance
at both time points is required to be considered 12-Month Clear.
Randomization Exclusion Criteria (12-months):
- Known pregnancy.
- Patient switched from prasugrel to other thienopyridine after discharge from index
- Patient switched maintenance dose of prasugrel (such as 10mg to 5mg; or 5mg to 10mg)
within 6-months prior to randomization.
- Percutaneous coronary intervention or cardiac surgery between 6 weeks post index
procedure and randomization.
- Planned surgery necessitating discontinuation of antiplatelet therapy (> 14 days)
within the 21 months following randomization.
- Patients on warfarin or similar anticoagulant therapy.
- Current medical condition with life expectancy of less than 3 years.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study